Thermo Fisher Scientific has announced its new Accelerator Drug Development platform, designed to offer 360° contract development and manufacturing organisation (CDMO) and contract research organisation (CRO) solutions to support the pharmaceutical industry.
A CPHI Milan 2024, Thermo Fisher will highlight its expanded global capabilities, including investments in research, manufacturing, and clinical trial services. The company aims to accelerate the drug development journey, from pre-clinical stages to commercialisation, through new facilities and technology upgrades across its global network.
Michael Shafer, Executive Vice President and President of Biopharma Services at Thermo Fisher, commented,
“Thermo Fisher is transforming drug development and manufacturing processes to support customers as they move critical programs forward to tackle global health challenges with speed, quality and efficiency.”
Thermo Fisher’s new bioanalytical lab in Sweden, expansions in oral drug development sites in the U.S., and a partnership with Stevanato Group to enhance drug delivery methods are among the key updates to its services. These initiatives reflect the company’s commitment to streamlining drug development and improving clinical research services worldwide.
The company is also collaborating with DHL Express to reduce emissions in clinical research logistics by using sustainable aviation fuel, marking a significant step toward more environmentally friendly research practices.
Overview of outsourcing trends 
